Risk factors for increasing multidrug resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species

被引:80
作者
Hyle, EP
Lipworth, AD
Zaoutis, TE
Nachamkin, I
Fishman, NO
Bilker, WB
Mao, XQ
Lautenbach, E
机构
[1] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[5] Childrens Hosp Philadelphia, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA
关键词
D O I
10.1086/429239
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The importance of infections due to extended-spectrum beta-lactamase - producing Escherichia coli and Klebsiella species (ESBL-EK) has been increasingly recognized in recent years. ESBL-EK infections are of clinical concern, because few antimicrobials are available as therapeutic options. Increased reliance on carbapenems has led to increasing carbapenem resistance. Efforts to maintain current therapeutic options for ESBL-EK infections are essential. Methods. We conducted a case-control study to identify risk factors for multidrug resistance (MDR) among ESBL-EK. All patients at our institution who had an inpatient clinical culture result positive for an ESBL-EK during the period of 1 June 1997 through 31 December 2002 were eligible for inclusion. An MDR ESBL-EK was defined as ESBL-EK demonstrating resistance to trimethoprim-sulfamethoxazole, aminoglycosides, and quinolones. All available ESBL-EK isolates were characterized by pulsed-field gel electrophoresis (PFGE). Results. Of 361 total ESBL-EK isolates, 68 (18.8%) were MDR. During the study period, the prevalence of MDR among ESBL-EK isolates increased from 12.5% to 26.9%. The only independent risk factor for MDR ESBL-EK was the infecting organism (i.e., Klebsiella pneumoniae; adjusted odds ratio, 11.7; 95% confidence interval, 4.77 - 28.51; P < .001). Prior antibiotic use was not independently associated with MDR ESBL-EK. PFGE patterns from K. pneumoniae isolates indicated close genetic relatedness among a substantial proportion of isolates. Conclusions. The emergence of MDR among ESBL-EK has important implications for the future ability to treat these infections. The strong association between the species of infecting organism and MDR suggests that the epidemiology in K. pneumoniae may be unique. PFGE results suggest that horizontal spread is important in the emergence of MDR ESBL-EK.
引用
收藏
页码:1317 / 1324
页数:8
相关论文
共 35 条
[1]   TESTS FOR LINEAR TRENDS IN PROPORTIONS AND FREQUENCIES [J].
ARMITAGE, P .
BIOMETRICS, 1955, 11 (03) :375-386
[2]   Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer membrane protein [J].
Bradford, PA ;
Urban, C ;
Mariano, N ;
Projan, SJ ;
Rahal, JJ ;
Bush, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) :563-569
[3]   CEFTAZIDIME RESISTANCE AMONG SELECTED NOSOCOMIAL GRAM-NEGATIVE BACILLI IN THE UNITED-STATES [J].
BURWEN, DR ;
BANERJEE, SN ;
GAYNES, RP .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (06) :1622-1625
[4]   CDC DEFINITIONS FOR NOSOCOMIAL INFECTIONS, 1988 [J].
GARNER, JS ;
JARVIS, WR ;
EMORI, TG ;
HORAN, TC ;
HUGHES, JM .
AMERICAN JOURNAL OF INFECTION CONTROL, 1988, 16 (03) :128-140
[6]   Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: A systematic review [J].
Harris, AD ;
Karchmer, TB ;
Carmeli, Y ;
Samore, MH .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (07) :1055-1061
[7]  
Hosmer D. W., 1989, APPL LOGISTIC REGRES, DOI DOI 10.1097/00019514-200604000-00003
[8]   Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: Evaluation of a national postmarketing surveillance program [J].
Itokazu, GS ;
Quinn, JP ;
BellDixon, C ;
Kahan, FM ;
Weinstein, RA .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) :779-784
[9]  
JACOBY GA, 1988, NEW ENGL J MED, V319, P723
[10]  
Jan IS, 1998, J FORMOS MED ASSOC, V97, P661